Heart attack

October 1, 2019

Cardiovascular Polypill-LAAH attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction: A four-component Polypill-LAAH consisting of Losartan(25 mg), Amlodipine (2.5 mg), Atorvastatin (10 mg), and Hydrochlorothiazide (12·5 mg)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 1/October/2019, 12.04 pm

Cardiovascular Polypill-LAAH attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction: A four-component Polypill-LAAH consisting of Losartan(25 mg), Amlodipine (2.5 mg), Atorvastatin (10 mg), and Hydrochlorothiazide (12·5 mg)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 1/October/2019, 12.04 pm https://genomediscovery.org/wp-content/uploads/2019/10/Poly-LAAH-attenuates-systolic-blood-pressure-and-LDL-cholesterol-level5.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/10/Poly-LAAH-attenuates-systolic-blood-pressure-and-LDL-cholesterol-level5.jpg October 1, 2019 October 1, 2019

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

September 26, 2019

Molecular mechanistic insight into how Dapagliflozin (DAPA) protects against and promotes functional recovery after Myocardial Infarction: Dapagliflozin (DAPA) (trade name: Forxiga, Farxiga, others), a medication used to treat type II diabetes, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 26/September/2019, 3.58 pm

Molecular mechanistic insight into how Dapagliflozin (DAPA) protects against and promotes functional recovery after Myocardial Infarction: Dapagliflozin (DAPA) (trade name: Forxiga, Farxiga, others), a medication used to treat type II diabetes, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 26/September/2019, 3.58 pm https://genomediscovery.org/wp-content/uploads/2019/09/Dapagliflozin-attenuates-cardiomyocyte-apoptosis-and-cardiac-ageing-through-up-regulation-of-PNUTS-and-other-genes-3.jpg 1280 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/09/Dapagliflozin-attenuates-cardiomyocyte-apoptosis-and-cardiac-ageing-through-up-regulation-of-PNUTS-and-other-genes-3.jpg September 26, 2019 September 27, 2019

What they say: A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of of the journal Nature, by Prof Dimmler…

September 25, 2019

Polypill for Cardioprotection: Polypill-HAAE/HAAV-based therapy for Cardiac repair and myocardial infarction: A four-component Polypill-HAAE/HAAV consisting of Hydrochlorothiazide (12·5 mg), Aspirin (81 mg), Atorvastatin (20 mg), and Enalapril (5 mg) or Valsartan (40 mg) increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 25/September/2019, 8.45 pm

Polypill for Cardioprotection: Polypill-HAAE/HAAV-based therapy for Cardiac repair and myocardial infarction: A four-component Polypill-HAAE/HAAV consisting of Hydrochlorothiazide (12·5 mg), Aspirin (81 mg), Atorvastatin (20 mg), and Enalapril (5 mg) or Valsartan (40 mg) increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 25/September/2019, 8.45 pm https://genomediscovery.org/wp-content/uploads/2019/09/PolypillHAEE.V-promotes-augments-proliferation-of-postnatal-cardiomyocyte-through-Agrin5.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/09/PolypillHAEE.V-promotes-augments-proliferation-of-postnatal-cardiomyocyte-through-Agrin5.jpg September 25, 2019 September 25, 2019

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

September 20, 2019

Senolytics therapy for cardiac repair, cardiac regeneration and cardioprotection: Combinatorial therapy for postnatal Cardiomyocyte proliferation, repair and regeneration: A two-component Pill consisting of Dasatinib and Quercetin (Pill-DQ) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 20/September/2019, 7.39 am

Senolytics therapy for cardiac repair, cardiac regeneration and cardioprotection: Combinatorial therapy for postnatal Cardiomyocyte proliferation, repair and regeneration: A two-component Pill consisting of Dasatinib and Quercetin (Pill-DQ) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 20/September/2019, 7.39 am https://genomediscovery.org/wp-content/uploads/2019/09/Treatment-with-Dasatinib-and-Quercetin-DAQ-Promotes-cardiac-proliferation.regeneration2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/09/Treatment-with-Dasatinib-and-Quercetin-DAQ-Promotes-cardiac-proliferation.regeneration2.jpg September 20, 2019 September 20, 2019

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

July 10, 2019

Little RNA may protect your heart from heart attack: Intracardiac injection of LncRNA Mirt2 attenuates pathogenesis-associated with Myocardial infarction: LncRNA Mirt2 decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 10/July/2019, 8.06 am

Little RNA may protect your heart from heart attack: Intracardiac injection of LncRNA Mirt2 attenuates pathogenesis-associated with Myocardial infarction: LncRNA Mirt2 decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 10/July/2019, 8.06 am https://genomediscovery.org/wp-content/uploads/2019/07/Intracardiac-epicardial-injection-of-LncRNA-Mirt2-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction-through-down-regulation-of-IRF3-GRK2-and-GMCSF4.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/07/Intracardiac-epicardial-injection-of-LncRNA-Mirt2-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction-through-down-regulation-of-IRF3-GRK2-and-GMCSF4.jpg July 10, 2019 July 10, 2019

July 6, 2019

Little RNA can save your heart from failing: Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA Mirt2 (Long non-coding RNA myocardial infarction associated transcript 2) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/July/2019, 10.25 pm

Little RNA can save your heart from failing: Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA Mirt2 (Long non-coding RNA myocardial infarction associated transcript 2) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/July/2019, 10.25 pm https://genomediscovery.org/wp-content/uploads/2019/07/LncRNA-Mirt2-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR128-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/07/LncRNA-Mirt2-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR128-1.jpg July 6, 2019 July 6, 2019

Popular Post